Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9137 USD | +2.65% | +48.33% | +27.43% |
Apr. 26 | VolitionRx Limited Announces Board Changes | CI |
Apr. 23 | VolitionRx Limited Launches In-Clinic in U.S. and Europe Through Antech | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+27.43% | 74.99M | C | ||
-20.45% | 10.82B | A- | ||
+43.17% | 3.25B | D+ | ||
-35.86% | 2.11B | C | ||
-17.21% | 2.08B | - | B- | |
-29.81% | 1.48B | C+ | ||
+17.56% | 1.02B | B- | ||
-4.37% | 733M | C+ | ||
-37.00% | 391M | C- | ||
-46.94% | 383M | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VNRX Stock
- Ratings VolitionRx Limited